News Wire

A new guideline from the American Cancer Society (ACS) provides clinicians with recommendations on key areas of clinical follow-up care for survivors of head-and-neck cancer—a growing population numbering approximately 436,060 individuals and accounting for 3% of all cancer survivors in the United…
Thirty-six experts in the field of Duchenne muscular dystrophy have signed a letter to the FDA saying that, based on existing scientific data, the agency should approve eteplirsen (Sarepta Therapeutics), which is awaiting a final verdict. The letter was delivered to the FDA’s Division of Neurology…
Mount Sinai Hospital is the first center in the U.S. to use a new cancer treatment consisting of luminescent chemotherapy-filled beads injected into tumors through the wrist. The minimally invasive treatment, using M1 LUMI beads (BTG plc) filled with doxorubicin, is available for patients with inoperable…
Patients undergoing a coronary artery bypass graft (CABG) procedure could pay vastly different sums for the operation depending on where they have it performed, according to a new study published in the American Journal of Cardiology. Researchers at the University of Iowa found that prices for CABG…
Scientists at the University of Leeds in the United Kingdom have answered a 25-year-old question about how a family of proteins allows bacteria to resist the effects of certain antibiotics. Proteins of the ABC-F family are a major source of antibiotic resistance in “superbugs,” such as Staphylococcus…
Promising data have been reported from an ongoing phase 2 trial of Reolysin (Oncolytics Biotech), a proprietary formulation of the human reovirus, in combination with paclitaxel in women with ovarian cancer. The randomized study is comparing paclitaxel monotherapy with paclitaxel plus Reolysin in patients…
Eagle Pharmaceuticals has received a complete response letter from the FDA for its ready-to-use, stable liquid intravenous formulation of bivalirudin (5 mg/mL in a 50-mL vial). The treatment is intended for use as an anticoagulant in patients 1) undergoing percutaneous coronary intervention (PCI) with…
Two studies in the phase 3 OCTAVE (Oral Clinical Trials for Tofacitinib in Ulcerative Colitis) program have met their primary endpoints. At week 8, a significantly greater proportion of patients receiving tofacitinib (Xeljanz, Pfizer) 10 mg twice daily (BID) were in remission compared with patients…
Singapore-based TauRx Pharmaceuticals has taken a slightly different approach to finding a treatment for Alzheimer’s disease (AD) than most other companies, according to a report posted on the BioSpace website. TauRx is studying LMTX, a second-generation tau aggregation inhibitor (TAI), in three international…
The FDA has announced a proposal to ban most powdered gloves in the United States. While the use of these gloves is decreasing, they pose an unreasonable and substantial risk of illness or injury to health care providers, patients, and other individuals who are exposed to them, which cannot be corrected…
Positive findings have been announced from a pivotal phase 3 trial of romosozumab (Amgen/UCB) in men with osteoporosis. The study met its primary endpoint, demonstrating a statistically significant increase in bone mineral density (BMD) at the lumbar spine (as assessed by dual-energy x-ray absorptiometry)…
When mutated, a gene known for its ability to repair DNA appears instead to cause breast cancer, scientists report. The gene, GT198, whether mutated by genetics, environmental factors, or both, has strong potential as a way to diagnose breast cancer early and as a new treatment target, said Dr. Lan…
 Scientists at Umeå Centre for Microbial Research (UCMR) have discovered chemical compounds that are able to attenuate the virulence of the bacterial human pathogen Listeria monocytogenes. Their findings were published in Cell Chemical Biology. The dramatic increase of antibiotic resistance makes…
Treatment with ustekinumab (Stelara, Janssen) induced clinical response and clinical remission in adult patients with moderate-to-severe Crohn's disease who had previously failed or were intolerant to treatment with one or more anti-tumor necrosis factor (TNF)-alpha therapies, according to phase 3 data…
Researchers funded by the National Institutes of Health (NIH) have discovered the cellular switch that boosts the activity of sperm cells so that they can travel to the egg. The finding may lead to new options for male contraception as well as treatments for infertility resulting from problems with…

Pages

Career Opportunities

HAP, a subsidiary of Henry Ford Health System, is a nonprofit health plan providing coverage to individuals, companies and organizations. This executive develops strategies to meet membership and revenue targets through products, pricing, market segmentation and advertising.  Aligns business among Business Development, Commercial Sales, Medicare and Public Sector Programs and Product Development. Seeks to enhance and be responsible for business development and expansion through the development of an effective product portfolio, strong interpersonal relationships and service excellence.

Apply via email to jfedder1@hfhs.org or online at http://p.rfer.us/HENRYFORDlXqAJA